INCY 25 Pill - white oval, 18mm
Generic Name: ruxolitinib
Pill with imprint INCY 25 is White, Oval and has been identified as Jakafi 25 mg. It is supplied by Incyte Corporation.
Jakafi is used in the treatment of Myelofibrosis; Polycythemia Vera; Graft-versus-host disease; Myeloproliferative Disorders and belongs to the drug class multikinase inhibitors. Risk cannot be ruled out during pregnancy. Jakafi 25 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for INCY 25
Jakafi
- Generic Name
- ruxolitinib
- Imprint
- INCY 25
- Strength
- 25 mg
- Color
- White
- Size
- 18.00 mm
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- Multikinase inhibitors
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Incyte Corporation
- National Drug Code (NDC)
- 50881-0025
- Inactive Ingredients
-
microcrystalline cellulose,
lactose monohydrate,
silicon dioxide,
hydroxypropyl cellulose (type e),
povidone,
sodium starch glycolate type A potato,
magnesium stearate
Note: Inactive ingredients may vary.
More about Jakafi (ruxolitinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (32)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
